Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 21.00p 19.00p 23.00p 21.00p 21.00p 21.00p 2,000 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.9 -7.8 -31.9 - 3.94

Genedrive Share Discussion Threads

Showing 26 to 44 of 50 messages
Chat Pages: 2  1
DateSubjectAuthorDiscuss
10/12/2018
14:52
Looks like Odey did not take part in the placing and prefered to take a bath - Message sent very clear - imo
pugugly
16/11/2018
09:48
Fundraising announced at 23p plus convertibles but from market reaction looks very much like a non event -
pugugly
10/10/2018
06:57
Anyone still following - Quiet as the grave here -
pugugly
02/10/2018
08:39
Genedrive (GDR) News Out Just Now http://crweworld.com/article/news-provided-by-globenewswire/822013/genedrive-to-release-genedrive-connect-mobile-app
danieldanj
24/8/2018
08:49
Woops!!!!! 656Public companies: duty of directors to call meeting on serious loss of capital (1)Where the net assets of a public company are half or less of its called-up share capital, the directors must call a general meeting of the company to consider whether any, and if so what, steps should be taken to deal with the situation. (2)They must do so not later than 28 days from the earliest day on which that fact is known to a director of the company. (3)The meeting must be convened for a date not later than 56 days from that day. (4)If there is a failure to convene a meeting as required by this section, each of the directors of the company who— (a)knowingly authorises or permits the failure, or (b)after the period during which the meeting should have been convened, knowingly authorises or permits the failure to continue,commits an offence. (5)A person guilty of an offence under this section is liable— (a)on conviction on indictment, to a fine; (b)on summary conviction, to a fine not exceeding the statutory maximum. (6)Nothing in this section authorises the consideration at a meeting convened in pursuance of subsection (1) of any matter that could not have been considered at that meeting apart from this section.
pugugly
02/11/2017
07:18
Sounds possibly fatal to the TB India programme ! https://www.investegate.co.uk/genedrive-plc--gdr-/rns/distribution-update-for-india/201711020700053351V/ Only questions are - * How much of a hit will the share price take today ? * What value is left in the company ?
pugugly
17/10/2017
13:37
Despite the rise in today’s share price, Genedrive’s results are poor. Revenue missed their £7m forecast and net losses widened to £6.4m, greater than their sales of £5.8m. The problems facing this diagnostic business is two-fold: -One R&D expenses account for 90% of group sales (normally you would expect 20%). Also, it grows larger as sales increase. -Two staff costs represent half of sales. Also, 40% of group sales is reliance on grant funding which is a volatile source of income. But, right now it is helping to mask internal sales weakness within the business. Those who participate in last year placing at 80p is down by 55%. For more Genedrive analysis and other analysis on companies’ results, click http://bit.ly/2hLViFb
walbrock82
16/10/2017
10:41
Bought in today for results pretty much MC in bank surely can't go wrong
johns288
05/7/2017
10:14
See previous
the ghost who walks
11/4/2017
06:34
Previous posts
the ghost who walks
30/3/2017
08:21
News. Following closely. See previous
the ghost who walks
27/3/2017
10:17
More news today. Monitoring this closely. R@d
the ghost who walks
17/3/2017
07:59
Previous posts
the ghost who walks
12/3/2017
19:16
See previois
the ghost who walks
11/3/2017
19:45
Yes, something positive. I've been trying to work out how big the HepC opportunity could be. Certainly a worthwhile addition to stable of clinical assets, it's just not going to be a game changer for the company. I have made clear my thoughts about the lack of ability with their R&D function. Nothing more to add sorry.
azzi
11/3/2017
19:45
Yes, something positive. I've been trying to work out how big the HepC opportunity could be. Certainly a worthwhile addition to stable of clinical assets, it's just not going to be a game changer for the company. I have made clear my thoughts about the lack of ability with their R&D function. Nothing more to add sorry.
azzi
17/2/2017
21:02
Looks like my contact was spot on re Epistems resistance to design changes. Sounds like there have been a few over inflated egos influencing the business. I thought the new CEO would have seen through them? Only chance of survival is a massive strategy shift!
azzi
17/2/2017
21:02
Looks like my contact was spot on re Epistems resistance to design changes. Sounds like there have been a few over inflated egos influencing the business. I thought the new CEO would have seen through them? Only chance of survival is a massive strategy shift!
azzi
31/1/2017
19:20
Had it confirmed again that Epistem were working with a world Leading company who strongly advised that they made design changes and improved the sample preparation and cartridge handling protocols. I understand Epistem turned down their recommendations. It appears these are the issues hitting the flagship Tb assay, and preventing its take up in India.
azzi
Chat Pages: 2  1
Your Recent History
LSE
GDR
Genedrive
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181211 13:38:31